Strategic Asset Sales TC BioPharm's recent sale of assets to CytoMed Therapeutics presents a potential opportunity to offer complementary asset management, licensing, or partnership services that facilitate future transactions or acquisitions.

Innovative Collaborations The company's ongoing partnerships with respected research institutions like Carnegie Mellon University and the University of Surrey suggest a readiness to adopt cutting-edge technology solutions, opening doors for advanced research tools, AI integration, and biotech infrastructure products.

Funding and Growth With recent non-dilutive grants and an $8M capital injection, TC BioPharm is positioned for accelerated research and development, creating potential demand for specialized laboratory equipment, manufacturing support, or project management services to sustain their growth.

Market Expansion Plans Developing treatments for infectious diseases such as Mpox and Monkeypox, along with potential acquisitions, indicates an expanding portfolio that can benefit from clinical trial services, regulatory consulting, and specialized medical supply providers targeting infectious disease therapies.

Technology Adoption The company's collaboration on AI solutions for donor matching and screening highlights a growing need for advanced data analytics, AI platforms, and software services to enhance their cell therapy development processes and improve patient outcomes.